Self-Reported Frequency and Impact of Hypoglycemic Events in Spain

Por Orozco-Beltrán, Domingo, Mezquita-Raya, Pedro, Ramírez de Arellano, Antonio, Galán, Manuel
Publicado em 2014

The Economic Burden of Insulin-Related Hypoglycemia in Spain

Por Parekh, Witesh, Hoskins, Nicki, Baker-Knight, James, Ramirez de Arellano, Antonio, Mezquita Raya, Pedro
Publicado no Diabetes Ther (2017)

Erratum to: The Economic Burden of Insulin-Related Hypoglycemia in Spain

Por Parekh, Witesh, Hoskins, Nicki, Baker-Knight, James, Ramirez de Arellano, Antonio, Mezquita Raya, Pedro
Publicado no Diabetes Ther (2017)

Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin

Por Mezquita Raya, Pedro, Pérez, Antonio, Ramírez de Arellano, Antonio, Briones, Teresa, Hunt, Barnaby, Valentine, William J.
Publicado em 2013

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin

Por Pérez, Antonio, Mezquita Raya, Pedro, Ramírez de Arellano, Antonio, Briones, Teresa, Hunt, Barnaby, Valentine, William J.
Publicado no Diabetes Ther (2015)

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain

Por Mezquita-Raya, Pedro, Ramírez de Arellano, Antonio, Kragh, Nana, Vega-Hernandez, Gabriela, Pöhlmann, Johannes, Valentine, William J., Hunt, Barnaby
Publicado no Diabetes Ther (2017)

Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study

Por Mezquita-Raya, Pedro, Reyes-Garcia, Rebeca, Moreno-Perez, Oscar, Escalada-San Martin, Javier, Ángel Rubio Herrera, Miquel, Lopez de la Torre Casares, Martin
Publicado no Diabetes Ther (2015)